Research Training in Pediatric Non-Malignant Hematology

项目总结/摘要 在此T32更新申请中，Aflac血液学培训计划（HTP）解决了以下关键需求： 培训儿科非恶性血液学的医生科学家和临床研究者的计划。 血液学的研究--特别是儿科--已经阐明了许多遗传、细胞和分子的 疾病过程的潜在机制，以及细胞分化等基本细胞功能 和基因调控。然而，尽管在过去的几十年里，血液学在科学和临床上取得了许多进展， 由NIH资助的血液学相关研究的研究者人数持续下降。HTP提供 在基础，转化研究博士后MD，MD/博士和博士研究员的严格培训，并在更新是 扩大到包括临床研究培训。在埃默里大学，建立了镰状细胞的研究项目， 疾病、止血和血栓形成、造血和干细胞生物学、基因治疗和红细胞生理学 和输血医学被纳入全国最大的儿科血液学临床项目， 为亚特兰大儿童保健中心的临床和转化研究提供了大量的患者。 与格鲁吉亚理工学院的合作伙伴关系扩大了34名教师导师，其中包括21名 实验室研究人员和13名临床研究人员获得了3700万美元的校外资金支持（1440万美元来自 联邦来源）。每个学员将有一个实验室和临床导师，以培养基础，翻译，或临床 儿科血液学相关研究。从14名青年中选出资深导师和初级导师配对 教师将扩大未来导师的供应。集成到非常成功的儿科 Aflac癌症和血液的血液学/肿瘤学/骨髓移植（BMT）奖学金计划 疾病中心，这个新的HTP已经支持了9名学员在其第一个3年半，并在更新将接纳2 研究员每年2年的支持，培养8 - 10名博士研究员和2 - 4名博士博士后研究员超过5年。 候选人将是Aflac和相关实验室以及外部的MD，MD/PhD和PhD研究员 候选人的选择，他们以前的培训，学术潜力，并致力于研究非恶性肿瘤 血液学除了严格的实验室研究培训外，受训人员还将参加关于开展 道德研究和提高再现性，部门职业发展研讨会，赠款写作和 学术技能培训、研究会议、期刊俱乐部和奖学金计划研究务虚会。个人 将为每个受训者制定培训计划，并通过多学科奖学金监测进展情况 监督委员会。受训人员将在当地和国家会议上介绍他们的工作，并开发应用程序 职业发展（K类）奖项。HTP利用埃默里大学广泛的研究资源 大学，包括临床和转化研究的正式课程和学位课程 通过埃默里的CTSA项目更新这T32将有助于培养下一代的学术 儿科非恶性血液学的领导者。

Project Summary/Abstract In this T32 renewal application, the Aflac Hematology Training Program (HTP) addresses the crucial need for programs to train physician scientists and clinical investigators in pediatric non-malignant hematology. Research in hematology – particularly in pediatrics – has elucidated many of the genetic, cellular and molecular mechanisms underlying disease processes, as well as fundamental cellular functions such as cell differentiation and gene regulation. Yet despite the many scientific and clinical advances in hematology over the past decades, the number of investigators funded by NIH for hematology related research continues to decline. This HTP offers rigorous training in basic, translational research to postdoctoral MD, MD/PhD and PhD fellows, and in renewal is expanded to include clinical research training. At Emory University, established research programs in sickle cell disease, hemostasis and thrombosis, hematopoiesis and stem cell biology, gene therapy, and red cell physiology and transfusion medicine are embedded in the largest clinical program in pediatric hematology in the country, providing huge patient volumes for clinical and translational research within Children’s Healthcare of Atlanta. Partnership with the Georgia Institute of Technology broadens the pool of 34 faculty mentors which includes 21 laboratory researchers and 13 clinical investigators supported by $37.0 M in extramural funding ($14.4 from Federal sources). Each trainee will have a laboratory and clinical Mentor to foster basic, translational, or clinical research relevant to pediatric hematology. Pairing of senior mentors with junior mentors from a pool of 14 young faculty members will expand the supply of future mentors. Integrated into the highly successful Pediatric Hematology/Oncology/Bone Marrow Transplant (BMT) Fellowship Program of the Aflac Cancer and Blood Disorders Center, this new HTP has supported 9 trainees over its first 3 ½ years, and in renewal will admit 2 fellows each year for 2 years of support, training 8-10 MD fellows and 2-4 PhD postdoctoral fellows over 5 years. Candidates will be MD, MD/PhD and PhD fellows within Aflac and associated laboratories, as well as external candidates chosen for their prior training, academic potential, and commitment to research in non-malignant hematology. In addition to rigorous laboratory research training, trainees will participate in courses on conduct of ethical research and enhancing reproducibility, departmental career development seminars, grant writing and academic skills training, research conferences, journal clubs, and fellowship program research retreats. Individual Training Plans will be developed for each trainee and progress will be monitored by multidisciplinary scholarship oversight committees. Trainees will present their work locally and at national meetings and develop applications for career development (K-type) awards. The HTP leverages the extensive research resources of Emory University, including formal course work and degree programs in clinical and translational research available through Emory’s CTSA program. Renewal of this T32 will contribute to training the next generation of academic leaders in pediatric non-malignant hematology.